NASDAQ-listed AGAPE ATP Corporation (ATPC) has taken a significant step in its expansion into Southeast Asia by signing three Memorandums of Understanding (MOUs) with leading healthcare institutions in Indonesia. These partnerships aim to propel medical research, enhance product safety, and tackle respiratory diseases like tuberculosis (TB) and chronic obstructive pulmonary disease (COPD).
Strategic Collaborations with Indonesian Institutions
The MOUs were signed with:
- Dr. Sardjito General Hospital (Yogyakarta)
- Dr. H. A. Rotinsulu Lung Hospital (Bandung)
- Dr. M. Goenawan Partowidigdo Respiratory Hospital (Bogor)
These partnerships focus on conducting clinical research on ATPC’s health products, ensuring they meet Indonesia’s health and safety standards prior to distribution. This initiative strengthens ATPC’s reputation as a trusted healthcare innovator, emphasizing compliance with local regulations and patient safety.
Driving Innovation in Healthcare
The partnerships align with ATPC’s vision of addressing critical global health challenges. Key initiatives include:
- Conducting advanced clinical studies for ATPC products such as DSY Wellness, ATP2, and LEGA.
- Fostering interdisciplinary collaboration to improve prevention, diagnosis, and treatment strategies for respiratory diseases.
- Offering training programs to enhance healthcare professionals’ skills.
- Establishing connections with international universities and specialist hospitals to raise healthcare standards.
Prof. Dato’ Sri Dr. How Kok Choong, ATPC’s Founder and Global Group CEO, highlighted the urgency of these efforts:
“TB and COPD are significant public health concerns in Indonesia and Malaysia. Collaborative efforts are essential to improving prevention, diagnosis, and treatment strategies for these diseases.”
Sustainable Healthcare and Global Standards
ATPC’s collaborations also align with the United Nations Sustainable Development Goals (UNSDG), emphasizing the integration of sustainable medical innovations to enhance long-term well-being. By conducting rigorous clinical studies in alignment with Indonesia’s Ministry of Health standards, ATPC aims to ensure its products effectively serve patients and meet the evolving demands of global healthcare.
Distinguished Attendance
The MoU signing ceremony featured prominent guests, including:
- Dr. Suranto M.Kes, Director of Health Service Governance, Indonesian Ministry of Health.
- Prof. Dr. Taruna Ikrar, Head of the Food and Drug Supervisory Authority (BPOM).
- ATPC representatives: Prof. Dato’ Sri Dr. How Kok Choong, Dr. John Vong, Deputy Chairman, and Dr. Fernando Cortizo, Executive Director.
A Vision for the Future
Through these partnerships, ATPC reinforces its leadership in wellness and healthcare innovation, addressing critical health issues while advancing research, education, and sustainable health outcomes in Southeast Asia.